Claims for Patent: 9,279,001

Summary for Patent: 9,279,001

Title:	Injection paradigm for administration of botulinum toxins
Abstract:	Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine.
Inventor(s):	Turkel; Catherine C. (Newport Coast, CA), Aurora; Sheena K. (Seattle, WA), Brin; Mitchell F. (Newport Beach, CA)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	13/863,522
Patent Claims:	1. A method for treating or reducing the occurrence of a headache in a patient with chronic migraine headaches, the method consisting essentially of: administration of abobotulinumtoxinA to the frontalis, corrugator, procereus, occipitalis, temporalis, trapezius and cervical paraspinal muscles of the patient that suffers from the migraine headache; wherein the botulinum neurotoxin is administered, to the frontalis at about from forty units to about 100 units divided among four sites of injection; to the corrugator at about from twenty units to about fifty units divided among two sites of injection; to the procerus at about from ten units to about twenty five units to one site of injection; to the occipitalis at about from sixty units to about one hundred fifty units divided among six sites of injection to about from eighty units to about two hundred units divided among eight sites of injection; to the temporalis at about from eighty units to about two hundred units divided among eight sites of injection up to from one hundred units to about two hundred fifty units divided among ten sites of injection; to the trapezius at about from sixty units to about one hundred fifty units divided among six sites of injection up to about from one hundred units to about two hundred fifty units divided among ten sites of injection and to the cervical paraspinal muscles at about from forty units to about one hundred units divided among four sites of injection; wherein abobotulinumtoxinA is injected at 31 to 39 injection sites. 2. The method of claim 1 wherein the total amount of abobotulinumtoxinA administered is from about 310 units to about 975 units. 3. A method for treating or reducing the occurrence of a headache in a patient with chronic migraine headaches, the method consisting essentially of: local administration of a botulinum neurotoxin to the frontalis, corrugator, procereus, occipitalis, temporalis, trapezius and cervical paraspinal muscles of the patient that suffers from the migraine headache; wherein the botulinum neurotoxin is administered, to the frontalis at about eighty units divided among four sites of injection; to the corrugator at about forty units divided among two sites of injection; to the procerus at about twenty units to one site of injection; to the occipitalis at about one hundred twenty units divided among six sites of injection to about one hundred sixty units divided among eight sites of injection; to the temporalis at about one hundred sixty units divided among eight sites of injection up to two hundred units divided among ten sites of injection; to the trapezius at about one hundred twenty units divided among six sites of injection up to about two hundred units divided among ten sites of injection and to the cervical paraspinal muscles at about eighty units divided among four sites of injection; wherein the botulinum neurotoxin is injected at 31 to 39 injection sites. 4. The method of claim 3 wherein the total amount of botulinum neurotoxin administered is from about 620 units to about 780 units of abobotulinumtoxinA. 5. The method of claim 3 wherein the botulinum neurotoxin is type B. 6. The method of claim 3 wherein the botulinum neurotoxin is type E. 7. The method of claim 3 wherein the botulinum neurotoxin is type A. 8. A method for treating or reducing the occurrence of a headache in a patient with chronic migraine headaches, the method consisting essentially of: administration of incobotulinumtoxinA to the frontalis, corrugator, procereus, occipitalis, temporalis, trapezius and cervical paraspinal muscles of the patient that suffers from the migraine headache; wherein incobotulinumtoxinA is administered, to the frontalis at about twenty units divided among four sites of injection; to the corrugator at about ten units divided among two sites of injection; to the procerus at about five units to one site of injection; to the occipitalis at about thirty units divided among six sites of injection to about forty units divided among eight sites of injection; to the temporalis at about forty units divided among eight sites of injection up to fifty units divided among ten sites of injection; to the trapezius at about thirty units divided among six sites of injection up to about fifty units divided among ten sites of injection and to the cervical paraspinal muscles at about twenty units divided among four sites of injection; wherein incobotulinumA is injected at 31 to 39 injection sites. 9. The method of claim 8 wherein the total amount of incobotulinumtoxinA administered is from about 155 units to about 195 units.

Details for Patent 9,279,001

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ipsen Biopharm Limited	DYSPORT	abobotulinumtoxina	For Injection	125274	04/29/2009		2030-03-30
Merz Pharmaceuticals Gmbh C/o Merz Pharmaceuticals Llc	XEOMIN	incobotulinumtoxina	For Injection	125360	07/30/2010		2030-03-30
Merz Pharmaceuticals Gmbh C/o Merz Pharmaceuticals Llc	XEOMIN	incobotulinumtoxina	For Injection	125360	11/20/2015		2030-03-30